Gtcr Investment XI LLC

GTCR Investment XI LLC sold 12,735,301 shares of SHC at $15.17, exiting position entirely for $193,169,045.57

GTCR Investment XI LLC completely exited its 12,735,301-share position in Sotera Health (SHC) on 2026-05-13, selling at $15.17 per share for total proceeds of $193,169,045.57. This represents a full liquidation of the director's holdings, distinct from partial reductions. The company trades at a P/E of 37.24 with net income of $26,589,000.00 on revenue of $280,045,000.00 (annual growth +5.7%), suggesting valuation elevation relative to earnings. SHC has declined 23.1% from its 52-week high and 4.7% over the last 30 days; the broader market context shows this sale occurred amid downward price momentum. At the same-ticker level, GTCR's prior 5 trades at SHC showed mixed timing: only 2 of 5 prior sales were well-timed at the 90-day mark, indicating inconsistent execution at this security. The full exit signal warrants investor attention given its scale and the current valuation and price-action environment.

GTCR Investment XI LLC sold 10,000,000 shares of Sotera Health at $15.27 on 2026-03-06 ($152.7M), reducing stake by 44.0%

GTCR Investment XI LLC, a director holding, liquidated 10,000,000 shares (44.0% of pre-transaction holdings), reducing its stake from 22,735,301 to 12,735,301 shares at $15.27 per share for $152,700,000.00 total. The sale occurs at a price that is now -27.3% from the 52-week high of $19.35, and the stock has declined -20.8% in the 30 days following the transaction and -16.8% over 90 days. In the same-ticker history at SHC, GTCR's prior 5 sales yielded mixed timing outcomes: 3 of the 5 prior sells proved well-timed at the 90-day mark (stock fell after the sale), though 2 were poorly timed. The cross-ticker track record shows a 66.67% well-timed rate on 6 prior sells (average -4.5% 90-day return), suggesting this insider has a history of selling before declines. The substantial reduction in an already-large institutional position warrants attention to the company's fundamentals and the director's forward guidance.

GTCR Investment XI LLC sold 6,480,000 shares of SHC at $16.33 on 2025-12-03; stake reduced from 29.22M to 22.74M shares (-22.2%)

GTCR Investment XI LLC, a director, executed a material reduction of its SHC position by selling 6,480,000 shares (totaling $105,818,400.00) on 2025-12-03 at $16.33 per share, lowering its stake from 29,215,301 shares to 22,735,301 shares—a -22.2% decrease. The sale occurs at $16.33 while the stock currently trades at $16.75 and stands within 4.2% of its 52-week high ($17.48), near the upper end of its 52-week range ($9.80–$17.48). Reviewing GTCR's same-ticker history at SHC, 2 of 3 measurable prior sells (2025-09-05 and 2024-09-06) showed negative 90-day returns, indicating some pattern of exiting before subsequent weakness; however, this current sale price is already near the 52-week peak, limiting the headroom for further appreciation. The company itself shows a high P/E of 83.75 alongside modest annual revenue growth of +4.9%, suggesting valuation is already stretched relative to earnings generation.

GTCR Investment XI sold 12,000,000 SHC shares at $15.65 on 2025-11-10 for $187.8M, cutting stake to 29.22M shares (-29.1% reduction).

GTCR Investment XI LLC, a director of Sotera Health, executed a material sale of 12,000,000 shares representing a 29.1% reduction in holdings, generating $187,812,000.00 in proceeds at $15.65/share. The transaction occurs as the stock trades at $16.25, roughly 3.8% below its 52-week high of $16.90, suggesting the sale was not driven by desperation pricing. Critically, GTCR's cross-ticker track record shows a 100.00% well-timed rate on 4 prior open-market sells (average 90-day return of -15.4%), and at this same ticker (SHC), 2 of 2 prior measurable sells were well-timed at the 90-day mark (with 90-day outcomes of +5.1% and -21.9%). The substantial size and leadership reduction merit monitoring against near-term price action and forward guidance, particularly given SHC's elevated P/E of 81.25 relative to its 4.9% annual revenue growth, though the meaningful director stake retention (29.22M shares post-trade) indicates continued material alignment.

GTCR Investment XI LLC sells 8,000,000 shares of SHC for $120.9M; a -16.3% reduction in holdings consistent with prior well-timed exits

GTCR Investment XI LLC divested 8,000,000 shares at $15.11 on 2025-09-05, reducing holdings from 49.22M to 41.22M shares. This sale is the insider's third major divestiture at Sotera Health: two prior sales at this ticker on 2024-09-06 and 2024-03-04 were both well-timed at the 90-day mark, with the 2024 sales followed by -13.7% and -21.9% declines respectively. The current $15.81 price sits -6.5% from the 52-week high of $16.91, within striking distance of the recent sale price, while the stock has risen 31.1% over 90 days. The insider's broader track record shows a 100.00% well-timed rate on cross-ticker sells, with an average 90-day return of -15.4%, though this pattern is earned on a small sample. The 197.62 P/E and modest $8.0M net income on $294.3M revenue suggest valuation compression risk relative to market expectations. Whether this sale signals conviction about subsequent weakness or represents portfolio rebalancing at elevated levels, the pattern of prior exits preceding material declines at this ticker merits tracking against near-term price behavior.

GTCR Investment XI LLC sold 10,000,000 shares of SHC at $15.03 on 2024-09-06 ($150.3M), reducing stake by 16.9% to 49,215,301 shares post-transaction.

GTCR Investment XI LLC, a director, executed a substantial $150.3M sale of 10,000,000 shares at $15.03, reducing its position by 16.9%. The sell occurs at a price 10.5% below the current market level of $16.80 and 13.1% below the 52-week high of $17.34. Notably, GTCR's cross-ticker track record shows a 100.00% well-timed rate across 2 prior sells with average 90-day returns of -16.2%, while at SHC specifically, the prior 2024-03-04 sale similarly preceded a 90-day decline of -21.9%. The current 90-day performance since the September transaction shows +38.5% upside, representing a marked departure from the historical pattern where GTCR's sales have typically been followed by weakness.